Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients

British Journal of Pharmacology

Volumn 168, Issue 7, 2013, Pages 1687-1706

  Xie, Cen ^a   Zhou, Jialan ^a   Guo, Zitao ^a   Diao, Xingxing ^a   Gao, Zhiwei ^a   Zhong, Dafang ^a   Jiang, Haoyuan ^b   Zhang, Lijia ^b   Chen, Xiaoyan ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b Jiangsu Hengrui Medicine Co Ltd   (China)

Author keywords

bioactivation; famitinib; hepatotoxicity; metabolism; quinone imine

Indexed keywords

5 HYDROXYLDEFLUOROFAMITINIB; ALDEHYDE DEHYDROGENASE; ANTINEOPLASTIC AGENT; CYSTEINE; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DRUG METABOLITE; FAMITINIB; N DESETHYL 5 HYDROXYLDEFLUOROFAMITINIB; N DESETHYLFAMINITIB; PROTEIN TYROSINE KINASE INHIBITOR; RECOMBINANT ENZYME; SHR 1020; SHR 116637; SHR 141227; SHR 141371; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CANCER PATIENT; CHEMICAL MODIFICATION; CLINICAL ARTICLE; COMPLEX FORMATION; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; DEAMINATION; DEFLUORINATION; DESETHYLATION; DRUG ABSORPTION; DRUG ACTIVATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG ELIMINATION; DRUG EXCRETION; DRUG FECES LEVEL; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG RETENTION; DRUG TRANSFORMATION; DRUG URINE LEVEL; ENZYME ACTIVITY; EPOXIDATION; FEMALE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LIVER CELL; LIVER TOXICITY; MALE; MAXIMUM PLASMA CONCENTRATION; MICROSOME; MOLECULAR MECHANICS; OPEN STUDY; PRIORITY JOURNAL; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TROUGH PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ADULT; ANTINEOPLASTIC AGENTS; BIOTRANSFORMATION; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HEPATOCYTES; HUMANS; INDOLES; ISOENZYMES; MALE; MICROSOMES, LIVER; MIDDLE AGED; NEOPLASMS; OXIDATION-REDUCTION; PYRROLES; RECEPTOR PROTEIN-TYROSINE KINASES; TISSUE DISTRIBUTION;

EID: 84875123649     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12047     Document Type: Article

References (39)

1. Ayoub WS, Geller SA, Tran T, Martin P, Vierling JM, Poordad FF, (2005). Imatinib (Gleevec)-induced hepatotoxicity. J Clin Gastroenterol 39: 75-77.
2. Baillie TA, Cayen MN, Fouda H, Gerson RJ, Green JD, Grossman SJ, et al,. (2002). Drug metabolites in safety testing. Toxicol Appl Pharmacol 182: 188-196.
3. Bello C, Houk B, Sherman L, Misbah S, Sarapa N, Smeraglia J, et al,. (2005). Effect of rifampin on the pharmacokinetics of SU11248 in healthy volunteers [abstract]. J Clin Oncol 23: 3078.
4. Bonvin A, Mesnil A, Nicolini FE, Cotte L, Michallet M, Descotes J, et al,. (2008). Dasatinib-induced acute hepatitis. Leuk Lymphoma 49: 1630-1632.
5. Bort R, Ponsoda X, Jover R, Gomez-Lechon MJ, Castell JV, (1999). Diclofenac toxicity to hepatocytes: a role for drug metabolism in cell toxicity. J Pharmacol Exp Ther 288: 65-72.
6. Cabebe E, Wakelee H, (2006). Sunitinib: a newly approved small-molecule inhibitor of angiogenesis. Drugs Today (Barc) 42: 387-398.
7. Dahlin DC, Miwa GT, Lu AY, Nelson SD, (1984). N-acetyl-p-benzoquinone imine: a cytochrome P-450-mediated oxidation product of acetaminophen. Proc Natl Acad Sci U S A 81: 1327-1331.
8. Eisen T, Sternberg CN, Robert C, Mulders P, Pyle L, Zbinden S, et al,. (2012). Targeted therapies for renal cell carcinoma: review of adverse event management strategies. J Natl Cancer Inst 104: 93-113.
9. Goodman VL, Rock EP, Dagher R, Ramchandani RP, Abraham S, Gobburu JV, et al,. (2007). Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res 13: 1367-1373.
10. Gschwind A, Fischer OM, Ullrich A, (2004). The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 4: 361-370.
11. Hartmann JT, Haap M, Kopp HG, Lipp HP, (2009). Tyrosine kinase inhibitors-a review on pharmacology, metabolism and side effects. Curr Drug Metab 10: 470-481.
12. Ho C, Davis J, Anderson F, Bebb G, Murray N, (2005). Side effects related to cancer treatment: CASE 1. Hepatitis following treatment with gefitinib. J Clin Oncol 23: 8531-8533.
13. Hukkanen J, Pelkonen O, Hakkola J, Raunio H, (2002). Expression and regulation of xenobiotic-metabolizing cytochrome P450 (CYP) enzymes in human lung. Crit Rev Toxicol 32: 391-411.
14. Kang P, Dalvie D, Smith E, Renner M, (2008). Bioactivation of lumiracoxib by peroxidases and human liver microsomes: identification of multiple quinone imine intermediates and GSH adducts. Chem Res Toxicol 22: 106-117.
15. Kim A, Balis FM, Widemann BC, (2009). Sorafenib and sunitinib. Oncologist 14: 800-805.
16. Lammert C, Einarsson S, Saha C, Niklasson A, Bjornsson E, Chalasani N, (2008). Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology 47: 2003-2009.
17. Li X, He Y, Ruiz CH, Koenig M, Cameron MD, Vojkovsky T, (2009a). Characterization of dasatinib and its structural analogs as CYP3A4 mechanism-based inactivators and the proposed bioactivation pathways. Drug Metab Dispos 37: 1242-1250.
18. Li X, Kamenecka TM, Cameron MD, (2009b). Bioactivation of the epidermal growth factor receptor inhibitor gefitinib: implications for pulmonary and hepatic toxicities. Chem Res Toxicol 22: 1736-1742.
19. Li X, Kamenecka TM, Cameron MD, (2010). Cytochrome P450-mediated bioactivation of the epidermal growth factor receptor inhibitor erlotinib to a reactive electrophile. Drug Metab Dispos 38: 1238-1245.
20. Liu W, Makrauer FL, Qamar AA, Janne PA, Odze RD, (2007). Fulminant hepatic failure secondary to erlotinib. Clin Gastroenterol Hepatol 5: 917-920.
21. Loriot Y, Perlemuter G, Malka D, Penault-Llorca F, Boige V, Deutsch E, et al,. (2008). Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy. Nat Clin Pract Oncol 5: 268-278.
22. Mueller EW, Rockey ML, Rashkin MC, (2008). Sunitinib-related fulminant hepatic failure: case report and review of the literature. Pharmacotherapy 28: 1066-1070.
23. Park BK, Kitteringham NR, O'Neill PM, (2001). Metabolism of fluorine-containing drugs. Annu Rev Pharmacol Toxicol 41: 443-470.
24. Smolarek TA, Higgins CV, Amacher DE, (1990). Metabolism and cytotoxicity of acetaminophen in hepatocyte cultures from rat, rabbit, dog, and monkey. Drug Metab Dispos 18: 659-663.
25. Socinski MA, Novello S, Brahmer JR, Rosell R, Sanchez JM, Belani CP, et al,. (2008). Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 26: 650-656.
26. 14C]sunitinib in rats, monkeys, and humans. Drug Metab Dispos 40: 539-555.
27. Speed W, Bello C, Peng G, Patyna S, Wu E, (2008). In vitro and in vivo metabolism of sunitinib in nonclinical species and humans. AACR Meeting Abstracts 2008: 1285.
28. Stepan AF, Walker DP, Bauman J, Price DA, Baillie TA, Kalgutkar AS, et al,. (2011). Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States. Chem Res Toxicol 24: 1345-1410.
29. Tafazoli S, O'Brien PJ, (2009). Amodiaquine-induced oxidative stress in a hepatocyte inflammation model. Toxicology 256: 101-109.
30. Tamai N, Miyasaka H, (2000). Ultrafast dynamics of photochromic systems. Chem Rev 100: 1875-1890.
31. Teng WC, Oh JW, New LS, Wahlin MD, Nelson SD, Ho HK, et al,. (2010). Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib. Mol Pharmacol 78: 693-703.
32. Teo YL, Saetaew M, Chanthawong S, Yap YS, Chan EC, Ho HK, et al,. (2012). Effect of CYP3A4 inducer dexamethasone on hepatotoxicity of lapatinib: clinical and in vitro evidence. Breast Cancer Res Treat 133: 703-711.
33. Villard PH, Herber R, Seree EM, Attolini L, Magdalou J, Lacarelle B, (1998). Effect of cigarette smoke on UDP-glucuronosyltransferase activity and cytochrome P450 content in liver, lung and kidney microsomes in mice. Pharmacol Toxicol 82: 74-79.
34. Washington C, Eli M, Bello C, (2003). The effect of ketoconazole (KETO), a potent CYP3A4 inhibitor, on SU011249 pharmacokinetics (PK) in Caucasian and Asian healthy subjects [abstract 553]. J Clin Oncol 22: 553.
35. Wen B, Moore DJ, (2011). Bioactivation of glafenine by human liver microsomes and peroxidases: identification of electrophilic iminoquinone species and GSH conjugates. Drug Metab Dispos 39: 1511-1521.
36. Xie C, Yu K, Zhong D, Yuan T, Ye F, Jarrell JA, et al,. (2011). Investigation of isomeric transformations of chlorogenic acid in buffers and biological matrixes by ultraperformance liquid chromatography coupled with hybrid quadrupole/ion mobility/orthogonal acceleration time-of-flight mass spectrometry. J Agric Food Chem 59: 11078-11087.
37. Xie C, Zhong D, Chen X, (2012). Identification of the ortho-benzoquinone intermediate of 5-O-caffeoylquinic acid in vitro and in vivo: comparison of bioactivation under normal and pathological situations. Drug Metab Dispos 40: 1628-1640.
38. Zhou A, Zhang W, Chang C, Chi Y, Wang J, (2011). Tolerability of famitinib malate: the preliminary results from phase I clinical trial. Chin J New Drugs 20: 1678-1690.
39. Zwick E, Bange J, Ullrich A, (2001). Receptor tyrosine kinase signalling as a target for cancer intervention strategies. Endocr Relat Cancer 8: 161-173.